彩色多普勒超声评估肝硬化门静脉高压症患者TIPS术后支架功能研究*

doi:10.3969/j.issn.1672-5069.2024.06.025

摘要/Abstract

摘要： 目的探讨彩色多普勒超声评估肝硬化并发门静脉高压症(PH)患者在接受经颈静脉肝内门体分流术(TIPS)术后支架功能的价值。方法 2020年1月～2022年12月我院诊治的136例肝硬化患者,经检测肝静脉压力梯度(HVPG)诊断PH,使用彩色多普勒超声测量门静脉血流速度(Vpv)、门静脉内径(Dpv)和门静脉血流量(Qpv),应用受试者工作特征(ROC)曲线评估门静脉血流动力学指标联合诊断肝硬化并发PH的效能。常规行TIPS术,使用数字减影血管造影(DSA)和超声评估支架功能。结果在本组136例肝硬化患者中,经HVPG检测,发现PH者62例(45.6%),对其中52例行TIPS术; 肝硬化并发PH患者Vpv为(13.1±2.3)cm/s,显著低于肝硬化非PH者【(15.9±3.2)cm/s,P<0.05】,而Dpv和Qpv分别为(1.3±0.3)cm和(626.8±106.8)mL/min,均显著高于肝硬化非PH者【分别为(1.1±0.2)cm和(499.9±97.2)mL/min,P<0.05】,在TIPS术后,PH组门脉指标恢复,与肝硬化非PH者比,无显著性差异【分别为(16.2±2.5)cm/s、(1.1±0.2)cm和(502.1±99.4)mL/min,P<0.05】;ROC曲线分析显示,Vpv、Dpv和Qpv联合诊断肝硬化并发PH的AUC为0.902(95%CI:0.849～0.955,P<0.05),其敏感度为79.0%,特异度为83.8%;52例接受TIPS治疗患者术后1年随访,经DSA检查发现8例(15.4%)存在支架功能障碍, 彩色多普勒超声诊断支架功能障碍与DSA诊断的一致性较强(Kappa=0.680,P<0.05),其敏感度为87.5%,特异度为90.9%,准确率为90.4%。结论彩色多普勒超声检查评估TIPS术后支架功能具有良好的临床应用价值。

关键词: 肝硬化, 门脉高压症, 彩色多普勒超声, 经颈静脉肝内门体分流术, 支架功能, 诊断

Abstract: Objective The aim of this study was to investigate assessment of stent function by color Doppler ultrasonography in patients with liver cirrhosis (LC) and portal hypertension (PH) after transjugular intrahepatic portosystemic shunt (TIPS). Methods 136 patients with LC were enrolled in our hospital between January 2020 and December 2022, and PH was defined as hepatic venous pressure gradient (HVPG)≥10 mmHg. Color Doppler ultrasonography was used to measure portal vein blood flow velocity (Vpv), portal vein diameter (Dpv) and portal vein blood flow (Qpv), and receiver operating characteristic (ROC) curve was applied to evaluate diagnostic efficacy of portal vein hemodynamic indicator combination in predicting PH. TIPS was performed routinely, and postoperative stent functions was assessed by color Doppler ultrasonography and digital subtraction angiography (DSA). Results Of 136 patients with LC in our series, PH was found in 62 cases(45.6%) based on HVPG measurement and 52 of them received TIPS; Vpv in patients with LC and PH was (13.1±2.3)cm/s, much lower than [(15.9±3.2)cm/s, P<0.05], while Dpv and Qpv were (1.3±0.3)cm and (626.8±106.8)mL/min, both much higher than [(1.1±0.2)cm and (499.9±97.2)mL/min, P<0.05] in cirrhotics without PH, and portal hemodynamic indicators restored to almost normal and showing no significant differences as compared to those in patients without PH [(16.2±2.5)cm/s, (1.1±0.2)cm and (502.1±99.4)mL/min, respectively, P<0.05]; ROC analysis showed that the AUC was 0.902(95%CI:0.849-0.955,P<0.05), with sensitivity (Se) of 79.0%, specificity (Sp) of 83.8%, when combination of Vpv, Dpv and Qpv in predicting PH; by end of one year follow-up in 52 patients after TIPS, DSA found stent dysfunction in 8 cases (15.4%), and consistency of ultrasonography was satisfactory (Kappa=0.680, P<0.05), with Se of 87.5%, Sp of 90.9%, and accuracy of 90.4%. Conclusion Color Doppler ultrasound has a good application in identifying stent dysfunction after TIPS in patients with LC and PH.

Key words: Liver cirrhosis, Portal hypertension, Color Doppler ultrasonography, Transjugular intrahepatic portosystemic shunt, Stent function, Diagnosis

陈思艳, 郭道宁, 邹晓攀, 漆家高. 彩色多普勒超声评估肝硬化门静脉高压症患者TIPS术后支架功能研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 899-902.

Chen Siyan, Guo Daoning, Zou Xiaopan, et al. Assessment of stent function by color Doppler ultrasonography in patients with liver cirrhosis and portal hypertension after transjugular intrahepatic portosystemic shunt[J]. Journal of Practical Hepatology, 2024, 27(6): 899-902.

参考文献

[1] Jachs M, Hartl L, Simbrunner B, et al. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient. J Hepatol, 2024, 80(5):744-752.
[2] Yu Q, Huang Y, Li X, et al. An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension. Cell Rep Med, 2022, 3(3):100563.
[3] Boike JR, Thornburg BG, Asrani SK, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol, 2022, 20(8):1636-1662.
[4] Lee HL, Lee SW. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls. Clin Mol Hepatol, 2022, 28(2):121-134.
[5] Gralnek IM, Camus Duboc M, Garcia-Pagan JC, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European society of gastrointestinal endoscopy (ESGE) guideline. Endoscopy, 2022, 54(11):1094-1120.
[6] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792.
[7] 北京医师协会门静脉高压专科医师分会,中国研究型医院学会肝病专业委员会门静脉高压学组,中国研究型医院学会肝病专业委员会.肝硬化门脉高压症多学科诊治(基于肝静脉压力梯度)专家共识.临床肝胆病杂志,2021,37(9):2037-2044.
[8] Zhang D, Wang T, Yue ZD, et al. Hepatic venous pressure gradient: Inaccurately estimates portal venous pressure gradient in alcoholic cirrhosis and portal hypertension. World J Gastrointest Surg,2023, 15(11):2490-2499.
[9] Hidaka H, Uojima H. Ultrasonography in the diagnosis of complications in patients with portal hypertension. J Med Ultrason (2001), 2022, 49(3):347-358.
[10] Larrue H, Bureau C. Transjugular intrahepatic portosystemic shunt in portal hypertension: How to go further while staying on track. Hepatology, 2023, 77(2):344-346.
[11] Turco L, Reiberger T, Vitale G, et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int, 2023, 43(6):1183-1194.
[12] Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology, 2024, 79(5):1180-1211.
[13] Balducci D, Montori M, De Blasio F, et al. The role of transjugular intrahepatic portosystemic shunt (TIPS) in treating portal hypertension in patients with hepatocellular carcinoma. Medicina (Kaunas), 2023, 59(6):1150.
[14] Artru F, Moschouri E, Denys A. Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome. Clin Res Hepatol Gastroenterol, 2022, 46(4):101858.
[15] Hermie L, Van Cauwenberghe L, Dhondt E, et al. Transjugular intrahepatic portosystemic shunts in pediatric portal hypertension: a systematic review and meta-analysis. J Vasc Interv Radiol, 2023, 34(8):1382-1398.
[16] Joseph A, Lopera J. Transjugular intrahepatic portosystemic shunt reductions. Semin Intervent Radiol, 2023, 40(1):44-54.
[17] Shalvoy MR, Ahmed M, Weinstein JL, et al. Transjugular intrahepatic portosystemic shunt and thrombectomy (TIPS-Thrombectomy) for symptomatic acute noncirrhotic portal vein thrombosis. J Vasc Interv Radiol, 2023, 34(8):1373-1381.
[18] Brown MA, Gueyikian S, Huffman S, et al. Transjugular intrahepatic portosystemic shunt reduction techniques. Semin Intervent Radiol, 2023, 40(1):27-32.
[19] Rêgo HMC, Medronha EF, Junior EZ, et al. Transjugular intrahepatic portosystemic shunt with transhepatic portal vein puncture guided by ultrasound: a technical alternative. Eur J Gastroenterol Hepatol, 2022, 34(1):112-116.
[20] Lamanna A, Mitreski G, Maingard J, et al. Ultrasound-guided portal vein puncture during transjugular intrahepatic portosystemic shunt: technique and experience of a quaternary liver transplant hospital. J Med Imaging Radiat Oncol, 2022, 66(1):60-67.
[21] Duong N, Healey M, Patel K, et al. Use of doppler ultrasound to predict need for transjugular intrahepatic portosystemic shunt revision. World J Hepatol, 2022, 14(6):1200-1209.

彩色多普勒超声评估肝硬化门静脉高压症患者TIPS术后支架功能研究^*

Assessment of stent function by color Doppler ultrasonography in patients with liver cirrhosis and portal hypertension after transjugular intrahepatic portosystemic shunt

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周隽, 张忠新, 徐海燕. 可视化瞬时弹性成像与声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 832-835.
[2]	朱中华, 胡均贤, 李炎. 索非布韦/达克拉韦治疗CHC患者血清血管性血友病因子和可溶性血管黏附因子1水平变化^*[J]. 实用肝脏病杂志, 2024, 27(6): 836-839.
[3]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[4]	唐敏, 曾理, 杨鑫荣. FibroTouch和声触诊组织量化成像参数评估血吸虫病性肝病患者肝纤维化临床研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 887-890.
[5]	董旭, 秦阳华, 廖威, 许明晓, 葛玲玲, 李成忠. 乙型肝炎肝硬化和慢加急性肝衰竭患者并发感染影响因素与预后分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 891-894.
[6]	魏唯, 初丽敏, 王超, 吴明, 平东兰, 池冰. 乙型肝炎肝硬化患者营养状况及肌少症发生率调查^*[J]. 实用肝脏病杂志, 2024, 27(6): 895-898.
[7]	马莉, 顾中盛, 李想. 内镜下套扎联合奥曲肽和埃索美拉唑治疗肝硬化并发食管静脉曲张破裂出血患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 903-906.
[8]	曾旺, 蔡晓曼, 葛尚. 肝内胆管细胞癌与肝细胞癌病灶MRI增强扫描表现差异分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 907-910.
[9]	丹巴玉珍, 程盼. 增强MRI检查诊断HCC价值研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 911-914.
[10]	杨佳欣, 杨紫郡, 陈卫. 双源CT双能量TNC技术图像质量与诊断肝细胞癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 915-918.
[11]	邓娜, 郑玉凤, 刘旭红, 韩晓兵, 丁碧娇, 曾纬阳, 刘娜红, 黄莹, 陈梅桂. CT动态增强扫描诊断原发性肝癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 919-922.
[12]	马紫瑶, 王超, 赵珏, 冯赟, 张铭, 梁凯轶. MRI诊断不典型肝脓肿临床应用价值分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 931-934.
[13]	王玲玲, 姚敏, 姚登福. 肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 953-956.
[14]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[15]	张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.